Axial Spondyloarthritis Pipeline: Drug Pipeline, Regulatory Events and Clinical Trials in the Spotlight| Insights by DelveInsight

·6 min read

The report offers the most up-to-date information on Axial Spondyloarthritis pipeline products being developed by notable companies such as Pfizer, Suzhou Zelgen Biopharmaceuticals, Clover Biopharmaceuticals, FunPep Co Ltd., Kinevant Sciences, Izana Bioscience, Mycenax Biotech, and UCB Biopharma, among others.

Los Angeles, June 17, 2021 (GLOBE NEWSWIRE) -- Axial Spondyloarthritis Pipeline: Drug Pipeline, Regulatory Events and Clinical Trials in the Spotlight| Insights by DelveInsight

The report offers the most up-to-date information on Axial Spondyloarthritis pipeline products being developed by notable companies such as Pfizer, Suzhou Zelgen Biopharmaceuticals, Clover Biopharmaceuticals, FunPep Co Ltd., Kinevant Sciences, Izana Bioscience, Mycenax Biotech, and UCB Biopharma, among others.

DelveInsight’s Axial Spondyloarthritis (axSpA) Pipeline Insights report offers exhaustive coverage of the emerging therapies in different stages of development from pre-clinical till late-stage, along with dormant, inactive, and abandoned therapeutic agents.

Some of the important takeaways from the Axial Spondyloarthritis Pipeline report:

  • Axial Spondyloarthritis Pipeline report offers an extensive analysis of 30+ key players and 30+ key therapies.

  • Axial Spondyloarthritis pipeline candidates are under evaluation in different stages of the clinical phase such as QX 002N, Jaktinib, SCB-808, FPP003, KIN-1901, Namilumab, ENIA11, and others expected to get launched in the foreseeable future.

  • Some of the key companies expanding the Axial Spondyloarthritis Pipeline are Qyuns Therapeutics, Suzhou Zelgen Biopharmaceuticals, Clover Biopharmaceuticals, FunPep Co Ltd., Kinevant Sciences, Izana Bioscience, Mycenax Biotech, UCB Biopharma, among others.

  • DelveInsight estimates that the late-stage products Bimekizumab and Tofacitinib are expected to have a major impact on the Axial Spondyloarthritis treatment market.

  • Therapies in development for axSpA focus on targets such as JAK/STAT, IL-17, tumor necrosis factor-alpha, and granulocyte-macrophage colony-stimulating factor (GM-CSF). These drugs are administered via oral, intravenous, subcutaneous, and topical routes.

  • Tofacitinib, sold under the brand Xeljanz, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. In November 2020, Pfizer Inc. announced positive results from a Phase 3 investigational study evaluating the safety and efficacy of tofacitinib in adults with active Ankylosing Spondylitis (AS).

  • Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F. It is in the phase 3 stage of development for the treatment of Axial Spondyloarthritis.

Request for Sample to know more about the therapies expected to make grab the maximum patient pool @ Axial Spondyloarthritis Emerging Therapies and Forecast

The Axial Spondyloarthritis Pipeline reports lay down a thorough coverage of the ongoing clinical trials, collaborations taking place in the domain, recent happenings in the Axial Spondyloarthritis pipeline space, and growth prospects across the Axial Spondyloarthritis domain.

Axial Spondyloarthritis: Overview

Axial Spondyloarthritis is a chronic, inflammatory rheumatic disease that affects primarily the axial joints leading to severe pain, stiffness, and fatigue. It starts with an early inflammatory phase in which there is no structural damage in the sacroiliac joints (non-radiographic disease) progressing to later stages in which structural damage is visible on X‑ray scans of the sacroiliac joints as erosions, sclerosis, or bony bridges (radiographic disease; also known as Ankylosing Spondylitis).

Discover more about the disease, treatments, and pipeline therapies @ axSpA Pipeline Assessment

Axial Spondyloarthritis Pipeline Drugs

Drug

Company

Phase

MoA

RoA

QX 002N

Qyuns Therapeutics

Phase I

Interleukin-17 inhibitors

Subcutaneous

Jaktinib

Suzhou Zelgen
Biopharmaceuticals

Phase II

Janus kinase 1,2,3 inhibitors

Oral

SCB-808

Clover
Biopharmaceuticals

Phase III

Tumour necrosis factor inhibitors

Subcutaneous

FPP003

FunPep Co Ltd.

Preclinical

Immunostimulants

NA

KIN-1901

Kinevant Sciences

Phase I

Granulocyte macrophage colony stimulating factor antagonists

Subcutaneous

Namilumab

Izana Bioscience

Phase II

Granulocyte macrophage colony stimulating factor antagonists

Subcutaneous

ENIA11

Mycenax Biotech

Phase III

Tumour necrosis factor inhibitors

Subcutaneous

Bimekizumab

UCB Biopharma

Phase III

IL17A protein inhibitors; IL17F protein inhibitors

Intravenous; subcutaneous

Request for Sample to know more @ Axial Spondyloarthritis Pipeline Analysis, Key Companies, and Futuristic Trends

Axial Spondyloarthritis Therapeutics Assessment

The Axial Spondyloarthritis Pipeline report presents a kaleidoscopic view of the axSpA emerging novel therapies segmented by Stage, Product Type, Route of Administration (RoA), Molecule Type, Target, and Mechanism of Action.

By Product Type

  • Mono

  • Combination

By Stage

  • Discovery

  • Pre-clinical

  • IND

  • Phase I

  • Phase II

  • Phase III

  • Pre-registration

By Molecule Type

  • Monoclonal Antibody

  • Peptide vaccine

  • Interleukin

  • Small molecule

  • Recombinant fusion proteins

By Route of Administration

  • Oral

  • Intravenous

  • Subcutaneous

  • Topical

By Mechanism of Action

  • Tumour necrosis factor inhibitors

  • Granulocyte-macrophage colony-stimulating factor antagonists

  • Interleukin-17 inhibitors

  • Janus kinase 1 inhibitors

  • Immunostimulants

  • IL17A protein inhibitors; IL17F protein inhibitors

By Targets

  • Tumour necrosis factor

  • Granulocyte-macrophage colony-stimulating factor

  • Interleukin-17

  • Janus kinase 1

  • IL17A protein

For rich insights into merging therapies and assessment, visit Axial Spondyloarthritis Pipeline: Emerging Novel Therapies

Scope of the Axial Spondyloarthritis Pipeline Report

Coverage: Global
Key Players: Izana Bioscience, UCB, Sun Pharma Global, Akeso Biopharma, Kinevant Sciences, Jiangsu Hengrui Medicine Co., Suzhou Zelgen Biopharmaceuticals, Clover Biopharmaceuticals, Mycenax Biotech, Boehringer Ingelheim, and Qyuns Therapeutics among others.
Key Axial Spondyloarthritis Pipeline Therapies: Namilumab , Bimekizumab, Tofacitinib, Tildrakizumab, AK-111, NDI 031232, Gimsilumab, QX002N, SHR-0302, Jaktinib, SCB-808, FPP003, KIN-1901, ENIA11, BI 730357, and QX002N among others.

Discover more about the report offerings @ axSpA Emerging Therapies, Treatments, and Ongoing Clinical Trials

Table of Contents

1

Report Introduction

2

Executive Summary

3

Axial Spondyloarthritis Disease Overview

4

axSpA Pipeline Therapeutics Comparative Analysis

5

Axial Spondyloarthritis Therapeutic Assessment

6

Axial Spondyloarthritis – DelveInsight’s Analytical Perspective

7

In-depth Commercial Axial Spondyloarthritis Assessment

8

Axial Spondyloarthritis Collaboration Deals

9

Late Stage Axial Spondyloarthritis Products (Phase III)

10

Mid-Stage Axial Spondyloarthritis Products (Phase II)

11

Early Stage Axial Spondyloarthritis Products (Phase I)

12

Pre-clinical and Discovery Stage axSpA Products

13

Inactive Axial Spondyloarthritis Pipeline Products

14

Key Axial Spondyloarthritis Products

15

Unmet Needs

16

axSpA Market Drivers and Barriers

17

Future Perspectives and Conclusion

18

Analyst Views

19

Key Axial Spondyloarthritis Companies

20

Appendix

Get in touch with our Business executive for Regulatory Analysis, Licensing Services, and Consulting Solutions

Related Reports

Axial Spondyloarthritis Market
DelveInsight's "Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast-2030" report.

Non-Radiographic Axial Spondyloarthritis Market
DelveInsight's "Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Insights, Epidemiology, and Market Forecast-2030" report.

Spondylolisthesis Market Insights
DelveInsight's “Spondylolisthesis Market Insights, Epidemiology, and Market Forecast-2030" report.

Ankylosing Spondylitis Market
DelveInsight’s ‘Ankylosing Spondylitis Market Insights, Epidemiology, and Market Forecast–2030’ report.

Global Kinase Inhibitor In Autoimmune Diseases Market
DelveInsight’s ‘Global Kinase Inhibitor in Autoimmune Diseases Market Insights and Market Forecast – 2030’ report.

Adenosine Deaminase Severe Combined Immunodeficiency Market
DelveInsight's "Adenosine Deaminase-Severe Combined Immunodeficiency Market Insights, Epidemiology, and Market Forecast-2030" report.

Adult-Onset Still Disease Market
DelveInsight’s “Adult-onset Still’s Disease Market Insights, Epidemiology, and Market Forecast – 2030” report.

Browse through our posts
ABSSSI Pipeline Analysis
Parkinson's Disease Risk Factors
Wearable Healthcare Devices Market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News

CONTACT: Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting